<DOC>
	<DOCNO>NCT02483637</DOCNO>
	<brief_summary>This study evaluate safety RejuvenAir Cryospray therapy treat symptomatic chronic bronchitis patient airflow restriction .</brief_summary>
	<brief_title>Safety Feasibility Study Rejuvenair™ Treating Chronic Bronchitis Patients</brief_title>
	<detailed_description>Prospective , open label , single arm study sequential accrual subject know chronic bronchitis . There two phase study . Phase A enroll 12 subject treat single lobe ass safety , feasibility histology/immunology . After review data Data Safety Monitoring Board , Phase B study would begin . In Phase B study , Phase A subject would remain two lobes treat . In addition 24 subject enrol upper low lobe treat assess safety , feasibility immunology .</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<criteria>Males female ≥40 ≤75 year age . Subject able read , understand , sign write Informed Consent order participate study . Subject agrees continue maintenance pulmonary/COPD medication duration study . Diagnosis chronic bronchitis ( CB ) chronic obstructive pulmonary disease ( COPD ) minimum two year . ( Chronic Bronchitis define clinically chronic productive cough 3 month 2 successive year patient cause productive cough exclude . ) Preprocedure post bronchodilator FEV1 great equal 30 % less equal 80 % predict within 3 month enrollment . Smoking history least 10 pack year . Nonsmoking minimum 6 month prior consent agrees continue smoke duration study . Subject able adhere undergo 3 ( 4 Phase A ) bronchoscope procedure include lung biopsy multiple MCS treatment opinion investigator Subject acute pulmonary infection pneumonia within prior 6 week study bronchoscopy . Subject CB and/or COPD exacerbation ( require steroid and/or antibiotic ) within 6 week prior study bronchoscopy , define treat physician Subject clinically significant bronchiectasis respiratory disease chronic bronchitis COPD . Diagnosis asthma onset 30 year age Subject bullous emphysema characterize large bulla &gt; 30 millimeter CT. Subject transplant . Subject inability walk &gt; 140 meter Subject PaC02 &gt; 8kPa , PaO2 &lt; 7kPa room air . Subject RVSP &gt; 45mmHg LVEF &lt; 45 % 2Dcardiac echo . Subject undergone lung surgery : pneumonectomy , lobectomy , bullectomy , lung volume reduction surgery Subject prior lung device procedure , include emphysema stent ( ) implant , lung coil , valve , lung denervation device emphysema . Subject unable temporarily discontinue use anticoagulant therapy : warfarin , Coumadin , LMWH , heparin , clopidrogel ( equal ) Subject &gt; 10 mg prednisolone/day . Subject serious medical condition , : uncontrolled congestive heart failure , uncontrolled angina , myocardial infarction past year , renal failure , liver disease , cerebrovascular accident within past 6 month , uncontrolled diabetes , hypertension , autoimmune disease uncontrolled gastric reflux Subject pregnant , nursing , plan get pregnant study duration . Subject receive chemotherapy within past 6 month expect receive chemotherapy participation study . Subject another clinical investigational study within 6 week baseline . Subject known sensitivity medication require perform bronchoscopy ( lidocaine , atropine , benzodiazepine ) . Subject another clinical investigational study within 6 week baseline .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>spray cryotherapy</keyword>
	<keyword>cryotherapy</keyword>
	<keyword>chronic bronchitis</keyword>
	<keyword>airflow restriction</keyword>
</DOC>